Moreover, these well-known targets are closely related to malignant phenotypes of TNBC, including tumorigenesis [17], cancer stemness [18, 19], metabolic reprogramming [20], and drug resistance [21], etc. Therefore, novel combination treatments that can overcome nuclear EGFR-mediated therapeutic resistance seem to be a promising anticancer strategy for TNBC. Here, EGFR is linked to cancer.